Aclaris Therapeutics, Inc. (ACRS) Free cash flow 2016–2025
Aclaris Therapeutics, Inc. (ACRS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$47.2MFY2025 · since FY2016: -$34.8M → -$47.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$47.2M | -133.8% |
| FY2024 | -$20.2M | +74.6% |
| FY2023 | -$79.6M | -16.8% |
| FY2022 | -$68.2M | -30.0% |
| FY2021 | -$52.4M | -34.2% |
| FY2020 | -$39.1M | +60.1% |
| FY2019 | -$98.1M | +4.0% |
| FY2018 | -$102.2M | -82.8% |
| FY2017 | -$55.9M | -60.5% |
| FY2016 | -$34.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ACRS financial trends
ACRS RevenueACRS Net incomeACRS Net marginACRS Gross profitACRS Gross marginACRS Operating incomeACRS Operating marginACRS Operating cash flowACRS Capital expendituresACRS Return on equityACRS Stock buybacksACRS Dividends paidACRS Total assetsACRS Total liabilitiesACRS Shareholders’ equityACRS overview →